




Searching News Database: plaque psoriasis
HSMN NewsFeed - 22 Dec 2020
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
HSMN NewsFeed - 24 Jul 2020
Bimekizumab Superior to Cosentyx(R) in Achieving Complete Psoriasis Skin Clearance
Bimekizumab Superior to Cosentyx(R) in Achieving Complete Psoriasis Skin Clearance
HSMN NewsFeed - 4 Jun 2020
Mylan and Lupin Receive European Marketing Authorization for Nepexto(R), Biosimilar Etanercept
Mylan and Lupin Receive European Marketing Authorization for Nepexto(R), Biosimilar Etanercept
HSMN NewsFeed - 13 Mar 2019
Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA(R)
Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA(R)
HSMN NewsFeed - 10 Dec 2018
Perrigo Announces the Launch of an AB Rated Generic Version of Topicort(R) Topical Spray 0.25%
Perrigo Announces the Launch of an AB Rated Generic Version of Topicort(R) Topical Spray 0.25%
HSMN NewsFeed - 26 Nov 2018
Perrigo Announces Tentative FDA Approval For The First To File Generic Version Of Ultravate(R) Lotion 0.05%
Perrigo Announces Tentative FDA Approval For The First To File Generic Version Of Ultravate(R) Lotion 0.05%
HSMN NewsFeed - 26 Oct 2018
Mayne Pharma Acquires FDA-approved halobetasol foam, Complementing US Dermatology Portfolio
Mayne Pharma Acquires FDA-approved halobetasol foam, Complementing US Dermatology Portfolio
HSMN NewsFeed - 28 Jun 2018
Lupin and Mylan Partner to Commercialize Enbrel(R) (Etanercept) Biosimilar
Lupin and Mylan Partner to Commercialize Enbrel(R) (Etanercept) Biosimilar
HSMN NewsFeed - 20 Oct 2017
Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
HSMN NewsFeed - 24 May 2017
Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application (BLA) For Tildrakizumab
Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application (BLA) For Tildrakizumab
HSMN NewsFeed - 16 Feb 2017
Valeant Receives FDA Approval Of SILIQ(TM) (Brodalumab) For Moderate-To-Severe Plaque Psoriasis
Valeant Receives FDA Approval Of SILIQ(TM) (Brodalumab) For Moderate-To-Severe Plaque Psoriasis
HSMN NewsFeed - 24 Jan 2017
Perrigo Announces FDA Approval Of Its First-To-File AB Rated Generic Version Of Topicort(R) Spray, 0.25%
Perrigo Announces FDA Approval Of Its First-To-File AB Rated Generic Version Of Topicort(R) Spray, 0.25%
HSMN NewsFeed - 1 Jul 2016
Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe
Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe
HSMN NewsFeed - 26 Feb 2016
Lilly Receives Positive CHMP Opinion for Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis
Lilly Receives Positive CHMP Opinion for Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis
HSMN NewsFeed - 25 Jan 2016
Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis
Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis
HSMN NewsFeed - 17 Jan 2016
BENEPALI(R), the First Etanercept Biosimilar Referencing Enbrel(R), Approved in the European Union
BENEPALI(R), the First Etanercept Biosimilar Referencing Enbrel(R), Approved in the European Union
HSMN NewsFeed - 4 Dec 2015
Samsung Bioepis' RENFLEXIS(R) Infliximab Biosimilar Receives Regulatory Approval in Korea
Samsung Bioepis' RENFLEXIS(R) Infliximab Biosimilar Receives Regulatory Approval in Korea
HSMN NewsFeed - 19 Aug 2014
Dermira Completes $51 Million Financing and Expands Management Team and Board of Directors
Dermira Completes $51 Million Financing and Expands Management Team and Board of Directors
HSMN NewsFeed - 29 Apr 2013
UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease
UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease
HSMN NewsFeed - 31 Jul 2012
Prometheus Launches New Monitoring Test To Help Guide Inflammatory Bowel Disease Management
Prometheus Launches New Monitoring Test To Help Guide Inflammatory Bowel Disease Management
HSMN NewsFeed - 10 May 2011
Abbott's HUMIRA(R) (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study
Abbott's HUMIRA(R) (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study
HSMN NewsFeed - 19 Feb 2009
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
HSMN NewsFeed - 22 Jan 2009
New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
HSMN NewsFeed - 18 Sep 2008
Enbrel(R) Shown to Deliver Long-Lasting Improvements in Psoriasis Patients' Quality of Life
Enbrel(R) Shown to Deliver Long-Lasting Improvements in Psoriasis Patients' Quality of Life
HSMN NewsFeed - 4 Sep 2008
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
HSMN NewsFeed - 8 Aug 2008
FDA Extends Review Timeline for Ustekinumab Biologic License Application Three Months
FDA Extends Review Timeline for Ustekinumab Biologic License Application Three Months
HSMN NewsFeed - 24 Jun 2008
NICE Recommends Abbott's Adalimumab (HUMIRA(R)) for the Treatment of Chronic Plaque Psoriasis
NICE Recommends Abbott's Adalimumab (HUMIRA(R)) for the Treatment of Chronic Plaque Psoriasis
HSMN NewsFeed - 18 Jun 2008
Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
HSMN NewsFeed - 4 Jun 2008
Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
HSMN NewsFeed - 16 Apr 2008
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
HSMN NewsFeed - 17 Mar 2008
Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)
Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)
HSMN NewsFeed - 22 Feb 2008
Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
HSMN NewsFeed - 4 Feb 2008
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
HSMN NewsFeed - 30 Jan 2008
PhotoMedex Receives Positive Reimbursement Decision from Blue Shield of California for XTRAC Laser System
PhotoMedex Receives Positive Reimbursement Decision from Blue Shield of California for XTRAC Laser System
HSMN NewsFeed - 19 Jan 2008
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
HSMN NewsFeed - 20 Dec 2007
Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
HSMN NewsFeed - 16 Nov 2007
Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
HSMN NewsFeed - 6 Nov 2007
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
HSMN NewsFeed - 15 Oct 2007
Clinical Studies Show REMICADE Reduces Incidence of Bowel Surgeries in Ulcerative Colitis Patients
Clinical Studies Show REMICADE Reduces Incidence of Bowel Surgeries in Ulcerative Colitis Patients
HSMN NewsFeed - 6 Aug 2007
XOMA Appoints Steven B. Engle President, Chief Executive Officer and Director
XOMA Appoints Steven B. Engle President, Chief Executive Officer and Director
HSMN NewsFeed - 12 Jul 2007
Barrier Therapeutics Announces Positive Phase 2 Data With Oral Rambazole in Moderate to Severe Psoriasis
Barrier Therapeutics Announces Positive Phase 2 Data With Oral Rambazole in Moderate to Severe Psoriasis
HSMN NewsFeed - 7 Jun 2007
Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
HSMN NewsFeed - 2 Apr 2007
Abbott Seeks U.S. and E.U. Regulatory Approval for HUMIRA(R) (Adalimumab) in Psoriasis
Abbott Seeks U.S. and E.U. Regulatory Approval for HUMIRA(R) (Adalimumab) in Psoriasis
HSMN NewsFeed - 23 Mar 2007
UCB Provides Update on CIMZIA(TM) for Crohn's Disease and Rheumatoid Arthritis in the US
UCB Provides Update on CIMZIA(TM) for Crohn's Disease and Rheumatoid Arthritis in the US
HSMN NewsFeed - 2 Feb 2007
Survey Indicates People with Chronic Moderate to Severe Plaque Psoriasis May Be Under-Treated
Survey Indicates People with Chronic Moderate to Severe Plaque Psoriasis May Be Under-Treated
HSMN NewsFeed - 2 Feb 2007
New Analyses Reinforce Efficacy of REMICADE(R) in Treatment of Severe Psoriasis
New Analyses Reinforce Efficacy of REMICADE(R) in Treatment of Severe Psoriasis
HSMN NewsFeed - 2 Feb 2007
REMICADE(R) Therapy Shown to Improve Productivity in Patients Treated for Chronic Plaque Psoriasis
REMICADE(R) Therapy Shown to Improve Productivity in Patients Treated for Chronic Plaque Psoriasis
HSMN NewsFeed - 23 Oct 2006
Data Show Treatment With Remicade(R) Reduced Hospitalizations for Ulcerative Colitis Patients By Half
Data Show Treatment With Remicade(R) Reduced Hospitalizations for Ulcerative Colitis Patients By Half
HSMN NewsFeed - 23 Oct 2006
Connetics Corporation and Stiefel Laboratories, Inc. Sign Definitive Merger Agreement
Connetics Corporation and Stiefel Laboratories, Inc. Sign Definitive Merger Agreement
HSMN NewsFeed - 19 Sep 2006
FDA Approves Connetics' Verdeso Foam for the Treatment of Mild-to-Moderate Atopic Dermatitis
FDA Approves Connetics' Verdeso Foam for the Treatment of Mild-to-Moderate Atopic Dermatitis
HSMN NewsFeed - 8 May 2006
Connetics Names Sunil Patel Vice President, Corporate Development and Strategy
Connetics Names Sunil Patel Vice President, Corporate Development and Strategy
Additional items found! 90

Members Archive contains
90 additional stories matching:
plaque psoriasis
(Password required)
plaque psoriasis
(Password required)